PEGBIO CO-B (02565) climbed more than 7%, reaching a peak of HK$38.66 and setting a new listing high. At the time of reporting, the stock was up 5.84% at HK$38.04 with trading volume of HK$18.89 million.

On the news front, PEGBIO recently released its interim results, showing other net income of RMB 178,000, research and development expenses of RMB 26.294 million, and a loss per share of RMB 0.25. The company stated that with PB-119's New Drug Application (NDA) having been accepted by the National Medical Products Administration, the company expects to commercialize PB-119 in China in the near future.

Following the listing, the company anticipates incurring costs related to operating as a public company. Due to the development status of drug candidates, potential collaboration timelines and terms with partners, regulatory approval schedules, and commercialization of drug candidates, financial performance is expected to fluctuate across different periods.

Additionally, the announcement revealed that PEGBIO has successfully established a pipeline matrix covering six drug candidates targeting chronic disease areas. The company's core strategy focuses on treating metabolic diseases and their complications. Through continuous innovation, internal assessments indicate that multiple drug candidates possess dual value potential as both "First-in-Class" (FIC) and "Best-in-Class" (BIC) treatments, establishing a solid foundation for future market competitiveness.